Advice
Recommended for restricted use within NHS Scotland.
REASONS FOR ADVICE.
This sustained release formulation of filgrastim can be used for reducing the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy within the context of current practice guidelines.
Pegfilgrastim is a pegylated form of colony stimulating factor (CSF), with a sustained duration of action allowing administration once per chemotherapy cycle. It has benefits of convenience for patients and staff.
Download detailed advice21KB (PDF)
Medicine details
- Medicine name:
- Pegfilgrastim (Neulasta®)
- SMC ID:
- 67/03
- Indication:
- Reducing the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 13 October 2003